Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.
A judge has expressed frustration over the fourth discovery fight this year in Fortescue’s trade secrets case against Element Zero, as the green iron startup claims its bigger rival is trying to drag out the litigation.
The High Court has rejected Novartis’ plea that it overturn a ruling that found an extension of the term of the patent for its heart drug Entresto was invalidly granted.
Green iron start-up Element Zero has said it will fight Fortescue’s bid to access nearly nine million documents collected under a controversial search order in the mining giant’s case alleging former employees misappropriated its process for carbon dioxide-free iron.
Sandoz has accused Amgen of ‘dragging the chain’ as the Swiss biotech continues to mull whether to launch infringement proceedings over six patents for its Prolia and Xgeve bone disease biologics.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
Green iron start-up Element Zero has lost its latest bid to set aside search orders in a case by Fortescue alleging former employees misappropriated its process for carbon dioxide-free iron.
Otsuka Pharmaceuticals is challenging a decision revoking its patent for an injectable version of antipsychotic drug Abilify.